ES2131060T3 - Intermedios modificados que contienen fosforo para proporcionar grupos funcionales en el extremo 5' de oligonucleotidos. - Google Patents

Intermedios modificados que contienen fosforo para proporcionar grupos funcionales en el extremo 5' de oligonucleotidos.

Info

Publication number
ES2131060T3
ES2131060T3 ES92306477T ES92306477T ES2131060T3 ES 2131060 T3 ES2131060 T3 ES 2131060T3 ES 92306477 T ES92306477 T ES 92306477T ES 92306477 T ES92306477 T ES 92306477T ES 2131060 T3 ES2131060 T3 ES 2131060T3
Authority
ES
Spain
Prior art keywords
carbon atoms
group
oligonucleotide
atoms
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92306477T
Other languages
English (en)
Inventor
David S Jones
John P Hachmann
Michael J Conrad
Stephen Coutts
Douglas Alan Livingston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Application granted granted Critical
Publication of ES2131060T3 publication Critical patent/ES2131060T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

SE UTILIZAN FOSFORAMIDITAS CON LA FORMULA EN DONDE R ES UN GRUPO PROTECTOR BASE-INESTABLE, R1 Y R2 SON INDIVIDUALMENTE ALQUILO DE 1 A 6 ATOMOS DE CARBONO, CICLOALQUILO DE 3 A 8 ATOMOS DE CARBONO O ARILO DE 6 A 20 ATOMOS DE CARBONO O SE UNEN JUNTOS PARA FORMAR CON EL ATOMO DE NITROGENO UNA ESTRUCTURA CICLICA DE 4-7 ATOMOS DE CARBONO Y DE 0 A 1 ATOMOS CALCOGENADOS ANULARES CON LOS NUMEROS ATOMICOS 8 A 16, G ES UN GRUPO HIDROCARBILENO DE 1 A 20 ATOMOS DE CARBONO Y Z ES UN GRUPO DIOL VECINAL HIDROXI-PROTEGIDO UNIDO A G POR UNO DE LOS ATOMOS DE CARBONO DEL DIOL VECINAL O UN GRUPO DISULFIDO Y UNIDO A G POR UNO DE LOS ATOMOS DE AZUFRE DEL GRUPO DISULFIDO, CON LA CONDICION DE QUE G TENGA, AL MENOS, 4 ATOMOS DE CARBONO CUANDO Z SEA DICHO GRUPO DISULFIDO EN LA SINTESIS AUTOMATIZADA CONVENCIONAL DE LOS OLIGONUCLEOTIDOS CON EL FIN DE INTRODUCIR UN ALDEHIDO FUNCIONAL O GRUPO TIOL EN EL EXTREMO 5'' DEL OLIGONUCLEOTIDO PARA PROPORCIONAR, DE ESTE MODO, UN PUNTO REACTIVO EN EL OLIGONUCLEOTIDO QUE SE PUEDE UTILIZAR PARA CONJUGAR EL OLIGONUCLEOTIDO CON MOLECULAS QUE CONTIENEN UN GRUPO AMINO LIBRE O UN CENTRO ELECTROFILICO REACTIVO CON UN GRUPO TIOL.
ES92306477T 1991-07-15 1992-07-15 Intermedios modificados que contienen fosforo para proporcionar grupos funcionales en el extremo 5' de oligonucleotidos. Expired - Lifetime ES2131060T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73105591A 1991-07-15 1991-07-15

Publications (1)

Publication Number Publication Date
ES2131060T3 true ES2131060T3 (es) 1999-07-16

Family

ID=24937868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92306477T Expired - Lifetime ES2131060T3 (es) 1991-07-15 1992-07-15 Intermedios modificados que contienen fosforo para proporcionar grupos funcionales en el extremo 5' de oligonucleotidos.

Country Status (13)

Country Link
EP (1) EP0523978B1 (es)
JP (3) JP2899111B2 (es)
AT (1) ATE179982T1 (es)
AU (3) AU664184B2 (es)
CA (1) CA2073846C (es)
DE (1) DE69229149T2 (es)
DK (1) DK0523978T3 (es)
ES (1) ES2131060T3 (es)
GR (1) GR3030260T3 (es)
HK (1) HK1014369A1 (es)
IE (1) IE922292A1 (es)
PT (1) PT100691B (es)
WO (1) WO1993002093A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
AU2003200284B2 (en) * 1998-03-27 2006-11-02 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
ATE313548T1 (de) * 1998-06-22 2006-01-15 Affymetrix Inc Reagenz und verfahren zu fester phase synthese
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2391944A1 (en) 1999-11-28 2001-06-14 Lajolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
DE10013600A1 (de) * 2000-03-18 2002-01-10 Aventis Res & Tech Gmbh & Co Reaktive Monomere für die Oligonucleotid- und Polynucleotidsynthese, modifizierte Oligonucleotide und Polynucleotiden und ein Verfahren zu deren Herstellung
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
DE10163836A1 (de) * 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
JP4495670B2 (ja) * 2005-12-27 2010-07-07 三井化学株式会社 メルカプトアルキルホスホニウム化合物の製造法
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012085064A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
CA2817448C (en) 2010-12-23 2019-01-22 F. Hoffmann-La Roche Ag Binding agent
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
FR2989086B1 (fr) 2012-04-04 2017-03-24 Centre Nat De La Rech Scient (Cnrs) Composes thiol et leur utilisation pour la synthese d'oligonucleotides modifies
FR2989089B1 (fr) * 2012-04-04 2020-02-07 Etablissement Francais Du Sang Oligonucleotides modifies comprenant des fonctions thiol et leur utilisation pour la detection d'acides nucleiques
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
US9884886B2 (en) 2012-12-06 2018-02-06 Merck Sharp & Dohme Disulfide masked prodrug compositions and methods
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2023192828A2 (en) * 2022-03-28 2023-10-05 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
TW202403044A (zh) * 2022-03-28 2024-01-16 美商安彼瑞可股份有限公司 經修飾之寡核苷酸

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3225063A (en) * 1962-05-21 1965-12-21 Scott Paper Co Organic cyclic carbonates
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
DK160818C (da) * 1983-12-30 1991-10-07 Hoffmann La Roche N-ring-holdige glycerolderivater, fremgangsmaade til fremstilling deraf, anvendelse deraf til fremstilling af et blodpladeaktiveringsfaktorhaemmende middel samt laegemidler indeholdende en saadan forbindelse
US4575558A (en) * 1984-02-15 1986-03-11 American Hospital Supply Corporation Preparation of optically active 1,3-dioxolane-4-methanol compounds
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5122450A (en) * 1985-10-24 1992-06-16 Research Corporation Limited Biochemical reagent
DE3811005A1 (de) * 1988-03-31 1989-10-19 Bayer Ag Thionophosphor(phosphon)saeureamidester
EP0354323A3 (en) * 1988-08-12 1990-06-13 American Cyanamid Company Antidiabetic phosphates
DE3916871A1 (de) * 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
DK0478686T3 (da) * 1989-06-22 1993-11-29 Alliance Pharma Flour- og phosphorholdige amphiphile molekyler med overfladeaktive egenskaber
DE3937116A1 (de) * 1989-11-03 1991-05-08 Dainippon Ink & Chemicals Verfahren zur herstellung cyclocarbonathaltiger ester

Also Published As

Publication number Publication date
DK0523978T3 (da) 1999-11-01
GR3030260T3 (en) 1999-08-31
PT100691A (pt) 1993-10-29
ATE179982T1 (de) 1999-05-15
JP2899111B2 (ja) 1999-06-02
DE69229149T2 (de) 1999-12-09
CA2073846C (en) 2007-09-18
EP0523978B1 (en) 1999-05-12
JP3488435B2 (ja) 2004-01-19
PT100691B (pt) 1999-06-30
IE922292A1 (en) 1993-01-27
JP2001302684A (ja) 2001-10-31
EP0523978A1 (en) 1993-01-20
AU686911B2 (en) 1998-02-12
HK1014369A1 (en) 1999-09-24
AU703715B2 (en) 1999-04-01
AU1968592A (en) 1993-01-21
WO1993002093A1 (en) 1993-02-04
JPH11228592A (ja) 1999-08-24
AU664184B2 (en) 1995-11-09
CA2073846A1 (en) 1993-01-16
JPH07500576A (ja) 1995-01-19
AU4058095A (en) 1996-03-14
DE69229149D1 (de) 1999-06-17
AU4520297A (en) 1998-02-19
JP3188243B2 (ja) 2001-07-16

Similar Documents

Publication Publication Date Title
ES2131060T3 (es) Intermedios modificados que contienen fosforo para proporcionar grupos funcionales en el extremo 5' de oligonucleotidos.
DE69133280D1 (de) Latente Katalysatoren, Härtungsinhibierte Epoxyharzzusammensetzungen und daraus hergestellte Laminate
ATE215568T1 (de) Hetero-telechele polymere und verfahren zu deren herstellung
ES2139022T3 (es) Recubrimiento de polisiloxano.
ATE284939T1 (de) Schmiermittelzusammensetzungen die eine molybdän- amine verbindung enthalten
DE3650760D1 (de) Polynukleotide und Proben mit Verwendung in Nukleinsäure-Sandwichassay in Lösungsphase
ATE120475T1 (de) Modifizierte disulfidpolymerzusammensetzungen und verfahren zu ihrer herstellung.
DK0710676T3 (da) Hærdelige overtrækssammensætninger indeholdende carbamatharpiks og additiver
PT775155E (pt) Derivados de estra-1,3,5(10)-trieno processo para a sua preparacao e composicoes farmaceuticas que contem estes compostos
BR9001734A (pt) Composto inseticida de diamino-etileno,processo para sua preparacao e composicao inseticida que o contem
TW253907B (es)
BR0102243A (pt) Processo para a preparação de dissulfetos orgânicos, e, uso do dissulfeto orgânico
KR910016818A (ko) 경화성 수지, 그의 제조 방법 및 전자부품용 보호막
ATE255560T1 (de) Urethangruppen enthaltende photoinitiatoren zur kationischen härtung
DE69822603D1 (de) Thermoplastisches kristallinpolyurethan und verfahren zu deren herstellung
MX9304293A (es) Metodo para curar cauchos sin la formacion de nitrosaminas.
ATE239765T1 (de) Polyesterharz zusammensetzung,gehärtetes harz und überzugsmittel
ES521376A0 (es) Procedimiento para preparar n-(1,3-ditiolan-2-ilideno)anilinas.
ES457575A2 (es) Procedimiento para la preparacion de un compuesto diarilico sulfurado ynu oxigenado.
ES2130754T3 (es) Fungicidas.
BR9713798A (pt) Composição de agente de cura, e, composição epóxi de dois componentes a base de solventes ou isenta de solventes.
ES8802300A1 (es) Un metodo para preparar derivados de 3-ariloxiazetidincarboxamida
DK0393778T3 (da) Silaner indeholdende mindst to oxazolidindele samt fremstilling og anvendelse deraf
DE59202543D1 (de) Härtbares Bindemittel und Verfahren zu dessen Herstellung.
BR8905907A (pt) Processo para a preparacao de um composto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 523978

Country of ref document: ES